4.8 Review

Metastasis as an evolutionary process

Journal

SCIENCE
Volume 352, Issue 6282, Pages 169-175

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aaf2784

Keywords

-

Funding

  1. Cancer Research UK [C50947/A18176]
  2. National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden Hospital
  3. Institute of Cancer Research [A109]
  4. Cancer Research UK (TRACERx project)
  5. Rosetrees Trust
  6. NovoNordisk Foundation [16584]
  7. European Union [259303]
  8. Prostate Cancer Foundation
  9. Breast Cancer Research Foundation
  10. European Research Council
  11. NIHR University College London Hospitals Biomedical Research Centre
  12. Cancer Research UK [18176] Funding Source: researchfish

Ask authors/readers for more resources

Therapeutic advances in oncology have not fully translated to the treatment of metastatic disease, which remains largely incurable. Metastatic subclones can emerge both early and late in the life of the primary tumor. A better understanding of the genetic evolution of metastatic disease has the potential to reveal differences in the therapeutic vulnerabilities of primary and metastatic tumors, shed light on the temporal patterns of and routes to metastatic colonization, and provide insight into the biology of the metastatic process. Here we review recent comparative studies of primary and metastatic tumors, including data suggesting that macroevolutionary shifts (the onset of chromosomal instability) contribute to the evolution of metastatic disease. We also discuss the practical challenges associated with these studies and how they might be overcome.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available